Based on information published by Johnson & Johnson Press Releases (linked below the article). Checked by an editor against the source before publication. How we report
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC
Source: Johnson & Johnson Press Releases
Important: this content is for informational purposes only and is not medical advice, a prescribing instruction, or a recommendation to act. Consult a licensed healthcare professional before taking any medication.
